Yakira Capital Management Inc. Invests $826,000 in Kenvue Inc. $KVUE

Yakira Capital Management Inc. purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 47,857 shares of the company’s stock, valued at approximately $826,000.

A number of other hedge funds have also recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC grew its stake in Kenvue by 11.9% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 212,574 shares of the company’s stock valued at $3,667,000 after purchasing an additional 22,614 shares in the last quarter. Venture Visionary Partners LLC acquired a new stake in Kenvue during the 4th quarter valued at approximately $426,000. P Schoenfeld Asset Management LP acquired a new stake in Kenvue during the 4th quarter valued at approximately $2,211,000. Panagora Asset Management Inc. grew its stake in Kenvue by 744.5% during the 4th quarter. Panagora Asset Management Inc. now owns 90,413 shares of the company’s stock valued at $1,560,000 after purchasing an additional 79,707 shares in the last quarter. Finally, Mariner LLC grew its stake in Kenvue by 84.5% during the 4th quarter. Mariner LLC now owns 578,669 shares of the company’s stock valued at $9,982,000 after purchasing an additional 265,048 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Down 0.1%

NYSE:KVUE opened at $18.13 on Monday. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average is $17.43 and its two-hundred day moving average is $17.54. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $22.87. The company has a market cap of $34.80 billion, a PE ratio of 21.32, a P/E/G ratio of 1.38 and a beta of 0.54.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter last year, the business posted $0.24 EPS. Kenvue’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, analysts predict that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 4.6%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.59% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on KVUE. Citigroup lowered their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Canaccord Genuity Group raised their price objective on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Barclays lowered their price objective on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. UBS Group lowered their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Finally, Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.